Postmenopausal hormone therapy in the aftermath of the WHI

Postgraduate Medicine

Volumn 113, Issue 3, 2003, Pages 15-20

  Cyr, Michele G ^a,b  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CALCIUM; ESTROGEN; LUBRICATING AGENT; MEDROXYPROGESTERONE; PROGESTERONE; VITAMIN D;

ALZHEIMER DISEASE; BONE MASS; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLOTHING; COLORECTAL CANCER; CORONARY ARTERY DISEASE; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG LABELING; DRUG SOLUBILITY; DRUG WITHDRAWAL; DYSTROPHY; ESTROGEN THERAPY; EXERCISE; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH SERVICE; HEART DISEASE; HERBAL MEDICINE; HIP FRACTURE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYSTERECTOMY; LONG TERM CARE; LOW DRUG DOSE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; MUSCLE RELAXATION; OSTEOPOROSIS; PATIENT SATISFACTION; POSTMENOPAUSE; PREVENTIVE MEDICINE; PRIMARY PREVENTION; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; SEXUAL BEHAVIOR; STIMULATION; STROKE; THROMBOEMBOLISM; UROGENITAL TRACT DISEASE; VAGINA MUCOSA; VASOMOTOR DISORDER;

EID: 0037336959     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2003.03.1394     Document Type: Review

References (8)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288(3):321-33
2. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280(7):605-13
3. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288(1):49-57
4. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEP1) Trial. The Writing Group for the PEP1 Trial. JAMA 1995; 273(3):199-208
5. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med 2002; 137(10):834-9
6. Gallagher JC, Rapuri PB, Haynatzki G, et al. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. J Clin Endocrinol Metab 2002;87(11):4914-23
7. Greendale GA, Espeland M, Slone S, et al. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. Arch Intern Med 2002;162(6):665-72
8. Hlatky MA, Boothroyd D, Vittinghoff E, et al. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/progestin Replacement Study (HERS) trial. JAMA 2002;287(5):591-7